AstraZeneca's new UK-based global R&D centre and corporate HQ will be located at the Cambridge Biomedical Campus on the southern outskirts of the city. By 2016, the new site will house a highly-skilled workforce of approximately 2,000, said an 18 June announcement.
The investment in a £330 million facility in Cambridge is part of the company’s move to create strategic global R&D centres in the UK, US and Sweden to improve pipeline productivity and to establish AstraZeneca as a global leader in biopharmaceutical innovation.
The purpose-built site in Cambridge will bring together AstraZeneca’s small molecule and biologics research and development activity, opening up opportunities to exploit the promise of small and large molecule combinations.
The Cambridge Biomedical Campus will be the new UK home for biologics research and protein engineering carried out by MedImmune, AstraZeneca’s biologics arm. MedImmune already employs around 500 people at Granta Park, to the south east of the city.
The new site will also become the company’s largest centre for oncology research as well as hosting scientists focused on cardiovascular and metabolic diseases, respiratory, inflammation and autoimmune diseases and conditions of the central nervous system.
Work carried out in Cambridge will include medicinal chemistry and high-throughput screening and the facility will accommodate a number of AstraZeneca’s pre-clinical research capabilities.
Other global functions will join the R&D teams at the new facility and Cambridge will become AstraZeneca’s corporate HQ.
The Cambridge Biomedical Campus site is home to leading research, academic and healthcare organisations including the University of Cambridge School of Clinical Medicine, Addenbrooke’s Hospital, the Medical Research Council (MRC) Laboratory of Molecular Biology, the Wellcome Trust-MRC Institute of Metabolic Science and the Cancer Research UK Cambridge Institute.
The AstraZeneca facility will occupy about 11 acres of the 70 acre campus in central Cambridge.
Wednesday, 26 June 2013 15:32
AstraZeneca selects Cambridge as global R&D/HQ hubWritten by Administrator
Latest from Administrator
- New Poultry Wastewater installation taken care of by Watermark Projects and Landia
- Tracking chemicals of concern in products – SCIP database ready for use
- ACWA Power to highlight its role as a global accelerator of energy transformation at the virtual WETEX 2020
- Eco Wave Power Develops a Game-Changing Wave Energy Power Plant Verification and Maintenance Software
- Brenntag will implement global transformation program to position the Group for sustainable organic earnings growth